Baird analyst Joe Vruwink upgrades Ncino (NASDAQ:NCNO) from Neutral to Outperform and announces $35 price target.
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples
Increase in the ratio of glycosylated αDG to total